Elbasha E - Search Results

1

Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance.

Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Hernandez-Avila M, Brown DR, Elbasha E, Muñoz N, Paavonen J, Haupt RM; FUTURE I Investigators. Insinga RP, et al. Among authors: elbasha e. Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):287-96. doi: 10.1158/1055-9965.EPI-10-0791. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21300618 Clinical Trial.

2

Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.

Insinga RP, Dasbach EJ, Elbasha EH. Insinga RP, et al. Pharmacoeconomics. 2005;23(11):1107-22. doi: 10.2165/00019053-200523110-00004. Pharmacoeconomics. 2005. PMID: 16277547 Review.

3

Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.

Dasbach EJ, Elbasha EH, Insinga RP. Dasbach EJ, et al. Epidemiol Rev. 2006;28:88-100. doi: 10.1093/epirev/mxj006. Epub 2006 Jun 1. Epidemiol Rev. 2006. PMID: 16740585 Review.

4

Model for assessing human papillomavirus vaccination strategies.

Elbasha EH, Dasbach EJ, Insinga RP. Elbasha EH, et al. Emerg Infect Dis. 2007 Jan;13(1):28-41. doi: 10.3201/eid1301.060438. Emerg Infect Dis. 2007. PMID: 17370513 Free PMC article.

5

Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives.

Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E. Insinga RP, et al. Among authors: elbasha eh. Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):709-15. doi: 10.1158/1055-9965.EPI-06-0846. Cancer Epidemiol Biomarkers Prev. 2007. PMID: 17416761 Clinical Trial.

6

Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women.

Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E. Insinga RP, et al. Among authors: elbasha eh. Infect Agent Cancer. 2007 Jul 12;2:15. doi: 10.1186/1750-9378-2-15. Infect Agent Cancer. 2007. PMID: 17626624 Free PMC article.

7

Global stability of equilibria in a two-sex HPV vaccination model.

Elbasha EH. Elbasha EH. Bull Math Biol. 2008 Apr;70(3):894-909. doi: 10.1007/s11538-007-9283-0. Epub 2007 Nov 13. Bull Math Biol. 2008. PMID: 17999117

8

Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation.

Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM. Insinga RP, et al. Vaccine. 2007 Dec 21;26(1):128-39. doi: 10.1016/j.vaccine.2007.10.056. Epub 2007 Nov 20. Vaccine. 2007. PMID: 18055075

9

The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.

Dasbach EJ, Insinga RP, Elbasha EH. Dasbach EJ, et al. Among authors: elbasha eh. BJOG. 2008 Jul;115(8):947-56. doi: 10.1111/j.1471-0528.2008.01743.x. Epub 2008 May 22. BJOG. 2008. PMID: 18503574

10

Structural differences among cost-effectiveness models of human papillomavirus vaccines.

Insinga RP, Dasbach EJ, Elbasha EH. Insinga RP, et al. Expert Rev Vaccines. 2008 Sep;7(7):895-913. doi: 10.1586/14760584.7.7.895. Expert Rev Vaccines. 2008. PMID: 18767941 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

80 results

Search Page

Filters